SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-324277
Filing Date
2019-12-27
Accepted
2019-12-27 09:03:03
Documents
3
Period of Report
2019-12-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.03: Bankruptcy or Receivership
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d857906d8k.htm 8-K 39332
2 EX-10.1 d857906dex101.htm EX-10.1 375980
3 EX-99.1 d857906dex991.htm EX-99.1 14196
  Complete submission text file 0001193125-19-324277.txt   431181
Mailing Address 44 WHIPPANY ROAD MORRISTOWN NJ 07963
Business Address 44 WHIPPANY ROAD MORRISTOWN NJ 07963 908 617-1309
MELINTA THERAPEUTICS, INC. /NEW/ (Filer) CIK: 0001461993 (see all company filings)

IRS No.: 454440364 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35405 | Film No.: 191311816
SIC: 2834 Pharmaceutical Preparations